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MDM2 and MDMX bind and stabilize the p53-related protein p73
Weg M. Ongkeko*†‡, Xiao Qi Wang§‡, Wai Yi Siu§, Anita W.S. Lau§,
Katsumi Yamashita¶, Adrian L. Harris†, Lynne S. Cox* and Randy Y.C. Poon§
The p53 gene encodes one of the most important tumor
suppressors in human cells and undergoes frequent
mutational inactivation in cancers. MDM2, a
transcriptional target of p53, binds p53 and can both
inhibit p53-mediated transcription [1,2] and target p53
for proteasome-mediated proteolysis [3,4]. A close
relative of p53, p73, has recently been identified [5,6].
Here, we report that, like p53, p73α and the alternative
transcription product p73β also bind MDM2. Interaction
between MDM2 and p53 represents a key step in the
regulation of p53, as MDM2 promotes the degradation
of p53. In striking contrast to p53, the half-life of p73
was found to be increased by binding to MDM2. Like
MDM2, the MDM2-related protein MDMX also bound
p73 and stabilized the level of p73. Moreover, the
growth suppression functions of p73 and the induction
of endogenous p21, a major mediator of the p53-
dependent growth arrest pathway, were enhanced in
the presence of MDM2. These differences between the
regulation of p53 and p73 by MDM2/MDMX may
highlight a physiological difference in their action.
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Results and discussion
MDM2 destabilizes p53 but stabilizes p73
Plasmids expressing MDM2 and hemagglutinin (HA)-
tagged versions of p73α and p73β (HA–p73α and
HA–p73β) were co-transfected into 293 cells. The expres-
sion levels of MDM2 and HA–p73 were detected by
immunoblotting with specific antibodies (Figure 1a). Sur-
prisingly, the levels of both p73α and p73β were much
higher when co-transfected with MDM2, compared with
cells transfected with p73 alone. Figure 1a also shows the
decrease in MDM2, and the lack of p73α elevation, in cells
transfected with the antisense MDM2 plasmid (lane 3).
Immunoblotting the same membrane for tubulin showed
similar loading of samples. As expected, co-expression of
Figure 1
MDM2 destabilizes p53 but stabilizes p73. (a) Embryonic kidney 293
cells were transfected with plasmids expressing HA–p73α, HA–p73β,
MDM2 and antisense MDM2 (αs) in the indicated combinations. Cells
were grown for a further 24 h after transfection and then harvested. Cell
extracts were prepared, electrophoresed on 7.5% SDS–polyacrylamide
gels and immunoblotted with antibodies against HA, HA and MDM2, or
HA and tubulin. The identity of the p73α bands was confirmed using an
antibody raised against a carboxy-terminal peptide of p73α (data not
shown). The positions of HA–p73α, HA–p73β, MDM2 and tubulin are
indicated. (b) The plasmid expressing p53 was co-transfected with a
control plasmid (lane 1), or with a plasmid expressing MDM2 (lane 2)
into 293 cells. Cell extracts were subjected to immunoblotting for
MDM2, p53, or p53 and tubulin. (c) Extracts from SAOS-2 cells
transfected with plasmids expressing HA–p73α (lanes 2,3) and MDM2
(lane 3) were subjected to immunoblotting with antibodies against
MDM2, or MDM2 and HA. Equal loading of samples was verified by
immunoblotting with antibodies against cyclin A or tubulin. (d) H1299
cells were transfected with a plasmid expressing HA–p73β (4 µg), and
an increasing amount of plasmid expressing MDM2 (lanes 1–5: 0 µg,
2 µg, 4 µg, 10 µg, 12 µg, respectively). Cell extracts were subjected to
immunoblotting for HA, MDM2 or tubulin.
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MDM2 with p53 reduced the level of p53 (Figure 1b).
Immunoblotting for p53 and tubulin together clearly indi-
cated that, although the level of tubulin remained constant,
p53 levels decreased when MDM2 was present. 
High transfection efficiency was achieved in 293 cells, but
these cells contained endogenous p53. To rule out the
involvement of p53 in these experiments, we also used the
p53-null SAOS-2 and H1299 cells. Co-expression of MDM2
increased the level of p73 in SAOS-2 cells (Figure 1c, only
p73α is shown). Moreover, a progressive increase in p73 was
seen when increasing amounts of MDM2 were co-trans-
fected into H1299 cells (Figure 1d; only p73β is shown).
Interestingly, transfection of p73α increased the level of
endogenous MDM2, suggesting that p73α can also activate
MDM2 transcription. These results clearly demonstrate
that p73 can be stabilized by MDM2 under conditions in
which p53 is destabilized, and suggest that the two closely
related proteins can be differentially regulated.
Association of p73 and transcriptionally inactive mutants
of p73 with MDM2
As the sequence of the MDM2-binding domain of p53
(TFSDLW in the single-letter amino-acid code) is similar
to that of p73 (TFEHLW), we next investigated whether
MDM2 could form a complex with p73. Figure 2a shows
that, when co-expressed with MDM2, both p73α and
p73β could be detected in MDM2 immunoprecipitates.
This result was verified in the reciprocal experiment in
which MDM2 was found in HA–p73 immunoprecipitates
but not in control immunoprecipitates (Figure 2b).
Figure 2b also shows that the transcriptionally inactive
mutants of p73α and p73β, in which the Arg292 residue
was mutated to His (R292H), could also bind MDM2, sug-
gesting that the transcriptional activity of p73 was not
required for the binding. To determine whether binding
of p73 to MDM2 was involved in the stabilization of p73
(see below), we created amino-terminal truncation
mutants (N∆250) of p73α and p73β and tested their
binding to MDM2. Figure 2c shows that only full-length
p73α, but not N∆250, could bind to MDM2 tagged with
glutathione S-transferase (GST). In support of some of the
findings described here, interaction between MDM2 and
p73 has also been reported recently [7,8].
Binding and stabilization of p73 by MDMX
MDMX is structurally similar to MDM2 but is not subject
to transcriptional activation by p53 [9]. A GST–MDMX
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Figure 2
Interaction between p73 and MDM2 or
MDMX. (a) HA–p73α, HA–p73β, MDM2 and
antisense MDM2 (αs) were expressed in
293 cells in the indicated combinations. Cell
extracts were subjected to immunoblotting
with antibodies against MDM2, or MDM2 and
HA. Cell extracts (100 µg) were
immunoprecipitated (IP) with an anti-MDM2
antibody, and immunoblotted with an anti-HA
antibody (bottom panel). The positions of
p73α, p73β, MDM2 and immunoglobulin G
(IgG) heavy chains from the
immunoprecipitation are indicated. (b) MDM2
was co-expressed in 293 cells with
HA–p73α, HA–p73β, HA–p73α(R292H) and
HA–p73β(R292H). Cell extracts (100 µg)
were immunoprecipitated with either anti-HA
antibody or an unrelated antibody as
indicated. The immunoprecipitates were
immunoblotted for MDM2, or MDM2 and HA.
(c) A plasmid encoding GST–MDM2 was co-
transfected into HtTA1 cells with plasmids
expressing HA–p73α, FLAG-epitope-tagged
p73α(N∆250) or p73β(N∆250), or vector
controls. Cell extracts (100 µg) were
incubated with GSH–agarose to isolate
GST–MDM2 and associated proteins as
described [10]. Total cell lysates (lanes 1–4)
and the GSH–agarose precipitates
(lanes 5–8) were immunoblotted for HA and
FLAG. (d) HA–p73α and GST–MDMX were
expressed in 293 cells in the indicated
combinations. Cell extracts were prepared
and subjected to immunoblotting for GST,
HA or tubulin. In the bottom panel, cell
extracts (100 µg) were incubated with
GSH–agarose as above, and immunoblotted
for HA.
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fusion was co-expressed with p73 in mammalian cells.
Figure 2d (only p73α is shown here) shows that p73α was
stabilized when co-expressed with GST–MDMX. To
study the possible interaction between p73 and MDMX,
cell extracts were incubated with agarose coupled to
reduced glutathione (GSH–agarose) to precipitate
GST–MDMX and any associated p73α. From Figure 2d,
it is apparent that p73α was only precipitated when co-
expressed with GST–MDMX. These data suggest that
MDMX, like MDM2, can bind to and stabilize p73.
MDM2 affects the half-life of p73
MDM2 regulates the level of p53 by targeting p53 for pro-
teasome-dependent degradation [3,4]. To determine
whether the elevation in p73 levels by MDM2 was due to
an increase in transcription of p73, we assessed the levels of
HA–p73α mRNA by RT–PCR. Figure 3a shows that the
relative level of HA–p73α mRNA was similar in the pres-
ence or absence of MDM2, suggesting that the effect of
MDM2 on p73 may be post-translational. Figure 3b shows
that, after treatment with LLnL, a proteasome/calpain
inhibitor, more HA–p73β was detected, suggesting p73β
may be degraded by a proteasome-dependent pathway. Sig-
nificantly, LLnL did not further increase the level of p73β
in the presence of MDM2, suggesting that MDM2 and
LLnL may both act on the same targets to promote p73 sta-
bility (that is, prevent proteasome-mediated degradation). 
For an initial idea of the half-life of p73, expression of p73
was turned off using cycloheximide (Figure 3c); we found
that p73 was more stable when co-expressed with MDM2.
For a better indication of the half-life, expression of p73
and N∆250 truncation mutants were put under the control
of deoxycycline. Figure 3d shows that, when co-expressed
with MDM2 (constant expression not under deoxycycline
control), the half-life of p73β was appreciably longer than
the control. In contrast, the half-life of the p73β (N∆250)
mutant was not affected by MDM2, suggesting that the
stabilization of p73 required interaction with MDM2. Sim-
ilarly, we found that amino-terminal deletion mutants of
MDM2 did not bind p53/p73, nor affect the protein level
of p53/p73 (our unpublished observations). Taken
together, these data suggest that the rate of degradation of
p73 can be decreased by binding to MDM2.
MDM2 enhances the anti-proliferative function of p73
We next investigated whether the biological functions of
p73 were influenced by MDM2. Figure 4a shows that the
endogenous p21 was induced by p73α but not by the tran-
scriptionally inactive R292H mutant. Significantly, co-
expression of MDM2 with p73α enhanced the induction
of p21. The growth potential of cells expressing p73 and
MDM2 was investigated by colony formation assays.
Expression of p73α reduced the number of colonies to
about 40% of the control (Figure 4b). Co-expression of
p73α with MDM2 further reduced the number of the
colonies (to about 15%). Our unpublished data also indi-
cate that co-expression of p73 and MDM2 increased the
sub-G1 DNA population in HeLa cells, suggesting that
induction of apoptosis by p73 was enhanced by MDM2. 
There are two distinct ways in which MDM2 can inacti-
vate p53. MDM2 can inhibit p53-mediated transcription
by masking the transactivating domain [1,2], as well as
targeting p53 for proteolysis [3,4]. Preliminary evidence
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Figure 3
Regulation of p73 protein level by MDM2. (a) Embryonic kidney
293 cells were transfected with the indicated combinations of
plasmids expressing HA–p73α and MDM2. The relative amount of
HA–p73α mRNA was analyzed by reverse transcriptase (RT)–PCR
using SP6 and T7 oligonucleotides. RT was excluded in lanes 4–6.
(b) A plasmid expressing HA–p73β was transfected into H1299 cells
with a vector control or with a plasmid expressing MDM2. After
transfection, the cells were divided into two identical plates (lanes 1,2:
vector; lanes 3,4: MDM2) and allowed to grow for 24 h. Buffer
(lanes 1,3) or LLnL (100 µM; lanes 2,4) was added to the medium, and
the cells incubated for another 12 h. Cell extracts were subjected to
immunoblotting for HA or tubulin. (c) A plasmid expressing HA–p73β
was co-transfected with a vector control (lanes 1–4) or with a plasmid
expressing MDM2 (lanes 5–8) into H1299 cells. Cycloheximide
(10 µg/ml) was added to the medium, and the cells were harvested at
the indicated times. Cell extracts were subjected to immunoblotting for
HA. (d) Plasmids carrying HA–p73β and FLAG–p73β(N∆250) under
inducible control of deoxycycline were co-transfected into HtTA1 cells
with a control plasmid (lanes 1–6) or with a plasmid expressing MDM2
(lanes 7–12). At 24 h after transfection, deoxycycline (1 µg/ml) was
added to the medium to turn off the expression of p73β and
p73β(N∆250). The cells were harvested at the indicated times for
extract preparation, and immunoblotted for HA or FLAG.
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indicated that MDM2 could also mask the transactivating
domain of p73, depending on the promoter and the cell
line used (our unpublished data). The relative impor-
tance of the stabilization of p73 versus the transcriptional
masking by MDM2 is currently under investigation. 
Materials and methods
DNA constructs
HA–p73 constructs in pcDNA3 were from W.G. Kaelin Jr. (Dana-
Farber Cancer Institute) [5]. FLAG-tagged N∆250 in pUHD-P1 was
constructed by putting the EcoRI–XbaI fragments of p73 in pcDNA3
into pUHD-P1 [10]. HA–p73 in pUHD-P1 was constructed by putting
the SacII–EcoRI fragment of p73α or p73β in pcDNA3 into
FLAG–p73(N∆250) in pUHD-P1. MDM2 in pCMV was a gift from B.
Vogelstein (Johns Hopkins Oncology Center), and murine p53 in
pCMV from T. Hunter (Salk Institute). Human MDMX was amplified by
RT–PCR from A549 cells, and subcloned into pCAGGS vector for
expression of GST–MDMX. The β-galactosidase construct was from Y.
Chen (Salk Institute), CD2 construct was from C. Norbury (University
of Oxford), and the CD20 construct was as described [10]. 
Cell culture
Transformed embryonic kidney 293 cells, non-small-cell lung carci-
noma H1299 cells and osteogenic sarcoma SAOS-2 cells were
obtained from the American Type Culture Collection. HtTA1 cells (gift
from H. Bujard) were HeLa cells (cervical carcinoma) stably transfected
with pUHD15-1 [11]. Cells were transfected using the calcium phos-
phate precipitation method [12]. Unless stated otherwise, cells were
transfected with 4 µg p73 DNA and 8 µg MDM2 DNA for 60 mm
plates, and the total amount of DNA for each transfection was adjusted
to the same level using vector DNA. Cells were grown for a further 24 h
for 293 cells, 36 h for H1299 cells, or 48 h for SAOS-2 cells after
transfection. Typical transfection efficiencies obtained were ~50%
(293 and HeLa), 20% (H1299) and 5–10% (SAOS-2). Cell-free
extracts were prepared as described [10]. For colony formation assays,
5 × 104 cells per 10 cm plate were transfected with a puromycin-resis-
tant plasmid, and allowed to grow for 48 h before 2 µg/ml puromycin
was added. After another 2 weeks, colonies were fixed with
methanol:acetic acid (2:1 v/v) and visualized by staining with 2% w/v
crystal violet. Around 500 colonies were counted for each experiment.
Antibodies and immunological methods
Mouse monoclonal antibody 421 against p53, E72 against cyclin A, rat
monoclonal antibody YL1/2 against tubulin, and rabbit anti-GST anti-
body were from T. Hunt (ICRF, South Mimms). Monoclonal antibody
12CA5 against the HA was from T. Hunter; 2A10 against MDM2 was
from A. Levine (Princeton University); M2 against FLAG was obtained
from Eastman Kodak; OX-34 against CD2 was from C. Norbury (Uni-
versity of Oxford). Goat anti-p73α polyclonal antibodies (sc-7238) and
rabbit anti-p21 antibodies (sc-397) were from Santa Cruz Biotechnol-
ogy. Immunoblotting and immunoprecipitations were performed as
described [10]. CD2-positive cells were selected by magnetic beads
according to the manufacturer’s instruction (DYNAL). 
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Figure 4
Inhibition of cell proliferation by p73 and MDM2. (a) H1299 cells were
transfected with plasmids expressing the CD2 surface marker (5 µg)
together with that expressing HA–p73α or HA–p73α(R292H) (5 µg),
or MDM2 (10 µg) in the combinations indicated. Transfected cells
were isolated by selection with magnetic beads coupled to anti-CD2
antibody. Cell extracts were prepared and immunoblotted with anti-
p21 or anti-tubulin antibody. (b) H1299 cells were transfected with a
plasmid that conferred puromycin-resistance, together with the control
vector, plasmids expressing MDM2 (10 µg), HA–p73α (6 µg), or
HA–p73α and MDM2 together, as indicated. The colony formation
assay was as described in Materials and methods. The average of
three independent experiments and the standard deviation are shown.
Note that the inhibition of colony formation by p73 was not 100%
because the puromycin-resistance gene and the p73 DNA were on
different plasmids, and only the integration of the puromycin-resistance
plasmid was selected for.
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